2019 American Transplant Congress
A Single-Center Experience with a 6-Month Regimen of Pneumocystis jiroveci Pneumonia Prophylaxis in HIV-Positive Kidney Transplant Recipients
*Purpose: Pneumocystis jiroveci pneumonia (PJP) prophylaxis is recommended for all kidney transplant recipients (KTR) for after transplant. HIV-positive KTRs represent a unique subset, and there…2019 American Transplant Congress
Azole Use and Fungal Pathogens in Cystic Fibrosis versus Non-Cystic Fibrosis Lung Transplant Recipients
*Purpose: Cystic fibrosis (CF) patients exhibit unique pharmacokinetic principles. Azole antifungals show marked inter- and intra-patient variability. We aimed to improve itraconazole (ITR) use and…2019 American Transplant Congress
Spontaneous Bacterial Peritonitis Prophylaxis Increases the Risk of Multi-Drug Resistant Cultures and Infections in Liver Transplant Patients
Columbia University Medical Center, New York, NY
*Purpose: Spontaneous bacterial peritonitis prophylaxis (SBP-P) is increasingly prescribed to patients awaiting liver transplantation (LT), but its impact on multidrug resistant organisms (MDRO) or the…2019 American Transplant Congress
Effect of Enoxaparin Prophylaxis on Early VTE Post Lung Transplant
*Purpose: Thromboembolic complications are common post-transplant leading to significant morbidity. We instituted early enoxaparin prophylaxis (ppx) in lung transplant recipients (LTR) due to an observed…2019 American Transplant Congress
Risk Stratification of Cytomegalovirus Seropositive Kidney Transplant Recipients for CMV Infection
1Yale University, New Haven, CT, 2University of Pennsylvania, Philadelphia, PA
*Purpose: Current consensus guidelines for CMV prevention recommend valganciclovir (VGCV) prophylaxis for 3 months after transplantation for CMV R+ kidney transplant recipients (KTR). This standard…2019 American Transplant Congress
Anti-Fungal Prophylaxis in Lung Transplant: A Systematic Review/Meta-Analysis
*Purpose: Invasive fungal infections (IFI) increase morbidity and mortality after lung transplant. Despite this, anti-fungal prophylaxis (AFP) in lung transplant recipients (LTR) varies by prophylactic…2019 American Transplant Congress
Use of a CMV Specific T Cell Immunity Assay in Late-Onset CMV Infection
*Purpose: To describe our clinical experience using a CMV Specific Cell Mediated Immunity (CMI) assay in solid organ transplant (SOT) recipients with late-onset CMV, defined…2019 American Transplant Congress
Retrospective Evaluation of Optimal Cmv Prophylaxis Regimens in Lung Transplant Patients: Analysis of Patient Outcomes Pre and Post Protocol Dosing Alterations
St. Joseph Hospital and Medical Center, Phoenix, AZ
*Purpose: Given the heightened risk of cytomegalovirus (CMV) following lung transplantation compared to other solid organ transplants, with minimal evidence based guidance specific to this…2019 American Transplant Congress
Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients
*Purpose: Letermovir is a new antiviral recently approved for cytomegalovirus (CMV) prophylaxis in CMV-seropositive hematopoietic-cell transplant recipients. Its off-label use in solid organ transplant (SOT)…2019 American Transplant Congress
Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir
*Purpose: Studies evaluating the efficacy of valganciclovir (VGC) at 450 mg daily versus 900 mg daily for the prevention of cytomegalovirus (CMV) in kidney transplant…
American Transplant Congress abstracts